Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331292 · ClinicalTrials.gov registry record
A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients
A clinical trial, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- 30
- Enrollment target
NCT00331292 is a clinical trial that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 30 participants.
The verdict
NCT00331292 was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The primary goal of this study is to identify a gene or panel of genes which are differentially expressed in lung cells and tissue from asthmatic patients following administration of Ipratropium bromide and eiTher nebulised Albuterol or saline. Each subject in this study will undergo two bronchoscopies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00331292
The ClinicalTrials.gov registry entry for NCT00331292 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00331292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00331292 about?
NCT00331292 is a clinical study titled "A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients". The primary goal of this study is to identify a gene or panel of genes which are differentially expressed in lung cells and tissue from asthmatic patients following administration of Ipratropium bromide and eiTher nebulised Albuterol or saline. Each subject in this study will undergo two bronchoscop...
What is the current status of trial NCT00331292?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2006-08.
Who is sponsoring clinical trial NCT00331292?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.